ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Synthetic Biologics Inc

Synthetic Biologics Inc (SYN)

1,02
0,00
(0,00%)
Fermé 02 Février 10:00PM
0,00
0,00
(0,00%)
Après les heures de négociation: -

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

Dernier
1,02
Prix Achat
-
Prix Vente
-
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,00 Plage de 52 semaines 0,00
Cap du marché
Clôture Veille
1,02
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume financier
-
VWAP
-
Volume moyen (3 m)
-
Actions en circulation
17 043 000
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-1,19
Bénéfice par action (BPA)
-1,08
Chiffre d'affairess
-
Bénéfice net
-18,35M

À propos de Synthetic Biologics Inc

Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbio... Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly used intravenous drugs for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antibiotic-resistant organisms. The company is also developing monoclonal antibody therapies for the treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria. Show more

Secteur
Pharmaceutical Preparations
Industrie
Business Services
Siège social
Rockville, Maryland, USA
Fondé
1993

SYN Dernières nouvelles

Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference

Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference PR Newswire ROCKVILLE, Md., Feb. 9, 2022 ROCKVILLE, Md., Feb. 9, 2022 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE...

Synthetic Biologics Announces VCN Biosciences' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA

Synthetic Biologics Announces VCN Biosciences' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA Follows recent announcement of planned acquisition of VCN Biosciences...

Synthetic Biologics to Present at the B. Riley Securities Oncology Conference on January 28, 2022

Synthetic Biologics to Present at the B. Riley Securities Oncology Conference on January 28, 2022 PR Newswire ROCKVILLE, Md., Jan. 26, 2022 ROCKVILLE, Md., Jan. 26, 2022 /PRNewswire/ -- Synthetic...

Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors

Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors Lead drug candidate...

Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET

Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET Initiated a Phase 1 Multiple Ascending Dose Clinical...

Synthetic Biologics to Report 2021 Third Quarter Operational Highlights and Financial Results on November 3, 2021

Synthetic Biologics to Report 2021 Third Quarter Operational Highlights and Financial Results on November 3, 2021 -- Conference Call Scheduled for Wednesday, November 3, 2021 at 4:30 p.m. ET...

Synthetic Biologics Announces Initiation of a Phase 1 Multiple-Ascending Dose Clinical Trial for SYN-020 Intestinal Alkaline Phosphatase

Synthetic Biologics Announces Initiation of a Phase 1 Multiple-Ascending Dose Clinical Trial for SYN-020 Intestinal Alkaline Phosphatase Topline Data Readout Expected in Q2 2022 Phase 1 Clinical...

Synthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

Synthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum The Company Encourages All Shareholders of Record Who Have Not Yet Voted to Do So by...

Synthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

Synthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum PR Newswire ROCKVILLE, Md., Sept. 21, 2021 ROCKVILLE, Md., Sept. 21, 2021 /PRNewswire/...

Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET

Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET Phase 1 Single-Ascending Dose Clinical Trial of...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

SYN - Frequently Asked Questions (FAQ)

What is the current Synthetic Biologics share price?
The current share price of Synthetic Biologics is US$ 1,02
How many Synthetic Biologics shares are in issue?
Synthetic Biologics has 17 043 000 shares in issue
What is the market cap of Synthetic Biologics?
The market capitalisation of Synthetic Biologics is USD 17,38M
What is the 1 year trading range for Synthetic Biologics share price?
Synthetic Biologics has traded in the range of US$ 0,00 to US$ 0,00 during the past year
What is the PE ratio of Synthetic Biologics?
The price to earnings ratio of Synthetic Biologics is -1,19
What is the reporting currency for Synthetic Biologics?
Synthetic Biologics reports financial results in USD
What is the latest annual profit for Synthetic Biologics?
The latest annual profit of Synthetic Biologics is USD -18,35M
What is the registered address of Synthetic Biologics?
The registered address for Synthetic Biologics is 9605 MEDICAL CENTER DRIVE, SUITE 270, ROCKVILLE, MARYLAND, 20850
What is the Synthetic Biologics website address?
The website address for Synthetic Biologics is www.syntheticbiologics.com
Which industry sector does Synthetic Biologics operate in?
Synthetic Biologics operates in the BUSINESS SERVICES sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
DXFEason Technology Limited
US$ 26,00
(57,29%)
895,37k
SGNSigning Day Sports Inc
US$ 3,73
(45,70%)
56,03M
CLDICalidi Biotherapeutics Inc
US$ 0,7629
(21,95%)
7,23M
XTNTXtant Medical Holdings Inc
US$ 0,6149
(15,50%)
99,67k
NNVCNanoViricides Inc
US$ 1,185
(10,75%)
684,82k
EXODExodus Movement Inc
US$ 50,00
(-18,54%)
155,49k
SENSSenseonics Holdings Inc
US$ 0,9609
(-11,84%)
17,03M
CPHIChina Pharma Holdings Inc
US$ 0,2183
(-9,91%)
325,86k
GOROGold Resource Corporation
US$ 0,3462
(-9,56%)
1,49M
EONREON Resources Inc
US$ 0,82
(-9,50%)
1,63M
SOXLDirexion Daily Semiconductor Bull 3X Shares
US$ 27,02
(-0,48%)
102,26M
SPXSDirexion Daily S&P 500 Bear 3X Shares New
US$ 5,82
(1,39%)
81,08M
TSLZT Rex 2X Inverse Tesla Daily Target ETF
US$ 2,3017
(-2,26%)
75,06M
NVDQT Rex 2X Inverse NVIDIA Daily Target ETF
US$ 3,565
(7,70%)
70,47M
SOXSDirexion Daily Semiconductor Bear 3X Shares New
US$ 20,61
(0,73%)
67,19M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock